Il-23-p19 vaccines

Abstract

Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHH-WETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, preferably M. Alzheimer or multiple sclerosis, atopic dermatitis, graft-versus-host disease, cancer, preferably Oesophagal carcinoma, colorectal carcinoma, lung adenocarcinoma, small cell carcinoma, and squamous cell carcinoma of the oral cavity, especially psoriasis, neurodegenerative diseases or IBD.

1 : A composition, comprising:
 the peptide according to  claim 14 , bound to a pharmaceutically acceptable carrier.   
     
     
         2 : The composition according to  claim 1 , wherein at least one cysteine residue is bound to an N- or C-terminus of the peptide. 
     
     
         3 : The composition according to  claim 1 , wherein at least one cysteine residue is bound to an N-terminus of the peptide. 
     
     
         4 : The composition according to  claim 1 , wherein the pharmaceutically acceptable carrier is a protein carrier. 
     
     
         5 : The composition according to  claim 4 , wherein the protein carrier is selected from the group consisting of keyhole limpet haemocyanin, tetanus toxoid and diphtheria toxin. 
     
     
         6 : The composition according to  claim 1 , wherein the composition is formulated with an adjuvant. 
     
     
         7 : The method according to  claim 17 , the administering comprises intravenous, subcutaneous, intradermal or intramuscular administration. 
     
     
         8 : The composition according to  claim 1 , wherein the peptide is contained in the composition in an amount from 0.1 ng to 10 mg. 
     
     
         9 : The composition according to  claim 1 , wherein the peptide is bound to the pharmaceutically acceptable carrier by a linker. 
     
     
         10 : The composition according to  claim 9 , wherein the peptide is bound to the pharmaceutically acceptable carrier by a peptide linker and the peptide linker is selected from the group consisting of Gly-Gly-Cys, Gly-Cys, Cys-Gly and Cys-Gly-Gly. 
     
     
         11 : The composition according to  claim 1 , wherein the composition is a biepitopic vaccine. 
     
     
         12 : The composition according to  claim 1 , wherein the composition comprises two peptides, each separately bound to a pharmaceutically acceptable carrier. 
     
     
         13 : A vaccine kit, comprising:
 the composition of  claim 1  and   a further composition against a disease selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes; atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.   
     
     
         14 : A peptide, selected from the group consisting of QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441), QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), QPEGHHWETQQIPS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWET (SEQ ID No. 108, p8461-1), QPEGHHWE (SEQ ID No. 109; p8462), TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762), and TQQIPSLS (SEQ ID No 115; p8763). 
     
     
         15 : A peptide pair, comprising:
 the peptide of  claim 14 ,   wherein a first peptide of the peptide pair is selected from the group consisting of QPEGHHWETQQIPS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWETQ (SEQ ID No. 98; p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109; p8462) and   a second peptide of the peptide pair is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99; p8400), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762) and TQQIPSLS (SEQ ID No 115; p8763).   
     
     
         16 : The composition according to  claim 1 , wherein the peptide is selected from the group consisting of QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441). 
     
     
         17 : A method of treating an interleukin 23 related disease, comprising:
 administering the composition of  claim 1  to a subject in need thereof,   wherein the interleukin 23 related disease is selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes; atherosclerosis, inflammatory bowel disease/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.   
     
     
         18 : The composition according to  claim 11 , wherein the biepitopic vaccine comprises a peptide selected from the group consisting of QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441), and QPEGHHWETQQI PSLS (SEQ ID No. 103; p8322). 
     
     
         19 : The composition according to  claim 12 ,
 wherein a first peptide is selected from the group consisting of QPEGHHWETQQI PS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWETQ (SEQ ID No. 98; p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109; p8462) and   a second peptide is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99; p8400), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762) and TQQIPSLS (SEQ ID No 115; p8763).